Related Experiment Video
Updated: May 9, 2026
08:47
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a)
Rebecca L Stead1, Christopher G Proud
1Centre for Biological Sciences, Building 85, University of Southampton, Southampton SO17 1BJ, United Kingdom.
FEBS Letters
|July 9, 2013
Summary
Rapamycin increases eIF4E phosphorylation in cancer cells by activating Mnk2, not Mnk1. This finding suggests combining mTOR and Mnk inhibitors may improve cancer therapy efficacy.
Area of Science:
- Molecular biology
- Cancer research
- Cell signaling
Background:
- Eukaryotic initiation factor 4E (eIF4E) and its phosphorylation are crucial in cell transformation and tumorigenesis.
- MAP kinase-interacting kinases (Mnks) phosphorylate eIF4E.
- Rapamycin treatment can increase eIF4E phosphorylation in cancer cells, potentially hindering its therapeutic effects.
Purpose of the Study:
- To investigate the mechanism behind rapamycin-induced eIF4E phosphorylation.
- To determine the specific Mnk isoforms involved in this process.
- To identify novel regulatory sites in Mnk2 activation.
Main Methods:
- Western blotting to detect protein phosphorylation.
- Kinase activity assays.
- Site-directed mutagenesis to investigate phosphorylation sites.
Main Results:
- Rapamycin-induced eIF4E phosphorylation is mediated by increased activity of Mnk2, not Mnk1.
- Activation of Mnk2 requires phosphorylation at a novel site, Ser437.
- This activation pathway is distinct from the canonical mTOR pathway targeted by rapamycin.
Conclusions:
- The findings reveal a novel regulatory mechanism for Mnk2 activity.
- Combining mTOR inhibitors (like rapamycin) with Mnk inhibitors, particularly those targeting Mnk2, could offer a more effective cancer treatment strategy than rapalogs alone.
- Understanding this pathway has significant implications for optimizing cancer therapy.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:25cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
01:16Calmodulin-dependent Signaling
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
01:31Regulation of the Unfolded Protein Response
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...